Hydrocodone is an opioid medication that is primarily used for the relief of moderate to severe pain, and in some cases, for the treatment of cough in patients for whom other medications are not effective.
Hydrocodone (Dosage)
Hydrocodone is a moderately potent opioid derived from morphine, which is usually administered orally in capsules or extended-release tablets to relieve severe and persistent pain. It is also widely used in combination with acetaminophen for the treatment of acute or chronic pain, and in combination with antihistamines or anticholinergics to treat cough.
It is important to know that hydrocodone has a high potential for abuse and dependence, as it acts on opioid receptors in the central nervous system.
MECHANISM OF ACTION
Hydrocodone is an agonist that binds to and activates opioid receptors in the brain and spinal cord. Hydrocodone can act directly as a weak agonist of the OPRM1 receptor or mu opioid receptor, but, once it is transformed into its active metabolite, hydromorphone, its affinity increases. Hydrocodone and its metabolites can also activate the delta opioid receptor OPRD1.
CONTRAINDICATIONS
- Significant respiratory depression
- Acute or severe bronchial asthma
- Gastrointestinal obstruction
- Hypersensitivity to hydrocodone or any component of the medication
SIDE EFFECTS
The most frequent adverse reactions are constipation, nausea, vomiting, fatigue, upper respiratory tract infection, dizziness, headache, drowsiness.
Severe respiratory depression may occur exceptionally, especially at the beginning of treatment or after an increase in dose.
People with kidney or liver failure have a higher risk of adverse effects.
INTERACTIONS
Hydrocodone can interact with other medications, especially with central nervous system depressants, such as anxiolytics, sedatives, muscle relaxants, and certain antidepressants (such as fluoxetine, paroxetine, and bupropion, which are strong CYP2D6 inhibitors). Alcohol consumption while being treated with hydrocodone is extremely dangerous, as it potentiates the depression of the central nervous system.
BRAND NAMES
- Hysingla®
- Lorcet®
- Norco®
- Tussionex®
- Vicodin®
- Zamicet®
Genes analyzed
Bibliography
Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021 Oct;110(4):888-896.
Peiró AM. Pharmacogenetics in Pain Treatment. Adv Pharmacol. 2018;83:247-273.
Smith DM, Stevenson JM, Ho TT, et al. Pharmacogenetics: A Precision Medicine Approach to Combatting the Opioid Epidemic. J Am Coll Clin Pharm. 2022 Feb;5(2):239-250.
